Disease Information for Sitagliptin (Januvia) Administration/Toxicity

Ads
Associated Diseases & Rule outs
Associated Disease & Complications
Drug induced Hypoglycemia
Hypoglycemia, diabetic/treatment
Pancreatitis, acute
Upper respiratory infection/cold/URI
Disease Mechanism & Classification
Drugs
DRUG/Anti-diabetic medication (example)
DRUG/Dipeptidyl peptidase-4 (DPP-4) inhibitor
DRUG/FDA Study 2006
DRUG/Glucagon Like Peptide GLP-1 Analog
DRUG/Increases levels on incretin/blocks DPP-4
DRUG/Incretin like anti-glycemic
DRUG/New release 2006
Synonyms
Synonym
Sitagliptin (Januvia) administration, Brand name/Janumet (Sitagliptin-Metformin) combination, Brand name/Januvia (Sitagliptin), Brand Name/Juvisync (Sitagliptin/DPP-4 and Simvastatin) Combination
Treatment
Drug Dosage
DRUG/Dose 100 mgm (Unit/Pill/Capsule size)
DRUG/Dose 25 mgm (Unit/Pill/Capsule size)
DRUG/Dose 50 mgm (Unit/Pill/Capsule size)
DRUG/Dose once daily (RX)
DRUG/Oral medication (ex)
-Renal excretion important pathway/drug
Definition

Oral drug for type II DM; Anti-diabetic dipeptidyl-peptidase-4 (DPP-4) increases GLP-1

(Glucagon like peptide4 -1) and increatin by inhibiting the breakdown of these molrecules. these trigger the pancreas to release more indsulin and liver to stop releasing/producing glucose at a more sensitive setting using the increatin hormon cascade; locally; oral drug novartis applying fda 2006 see also galvus by novartis

(Edit)

External Links Related to Sitagliptin (Januvia) Administration/Toxicity
Google
Wikipedia
Merck
Images
PubMed (National Library of Medicine)
NGC (National Guideline Clearinghouse)
Medscape (eMedicine)
Harrison's Online (accessmedicine)
NEJM (The New England Journal of Medicine)
Ads